Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides^*

References

• Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19–24
   PubMed Web of Science ®Google Scholar
• Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Exp Opin Invest Drugs 2001;10:721–31
   PubMed Web of Science ®Google Scholar
• Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue selections. Exp Eye Res 1998;67:179–91
   PubMed Web of Science ®Google Scholar
• Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100: 1297–304
   Google Scholar
• Toris CB, Camras CB, Yablonski ME, et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997;41(Suppl 2):S69–75
   PubMed Web of Science ®Google Scholar
• Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351–8
   PubMed Web of Science ®Google Scholar
• Alm A, Stjemschantz J, for the Scandinavian Latanoprost Study Group. Effects of intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995;102: 1743–1752
   Google Scholar
• Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily in patients with elevate intraocular pressure. Surv Ophthalmol 2001;45(Suppl 4):S361–8
   Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–84
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. Ophthalmology 2005;112:1177–85
   PubMed Web of Science ®Google Scholar
• Martínez García A, Perez García R. Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma [in Spanish]. Arch Soc Esp Oftalmol 2002;77:269–74
   Google Scholar
• Noecker RS, Dirks MS, Choplin NT, et al., for the Bimatoprost/ latanoprost study group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55–63
   Google Scholar
• Heel RC, Brogden RN, Speight TM, et al. Timolol a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979;17:38–55
   PubMed Web of Science ®Google Scholar
• Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 2000;17: 477–96
   Google Scholar
• Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998;105:1945–51
   PubMed Web of Science ®Google Scholar
• Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998;105:1952–9
   Google Scholar
• Fechtner R, Airaksinen PJ, Getson AJ, et al. For the Copsopt/ Xalatan study groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (CosoptTM) versus latanoprost 0.005% (XalatanTM) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82: 42–8
   Google Scholar
• Martinez A, Sanchez M. A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr Med Res Opin 2006;22:67–73
   Google Scholar
• SPSS (computer program). Version 12.0. SPSS Inc.; Chicago, IL, USA, 2004
   Google Scholar
• Watson P, Stjernshantz J. A six-month randomized, double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. The Latanoprost study Group. Ophthalmology 1996;103:126–37
   PubMed Web of Science ®Google Scholar
• Shin DH, Feldman RM, Sheu WO, for the fixed combination latanoprost/timolol study group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111:276–82
   Google Scholar
• Parmaksiz S, Yüksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 2006;15:73–80
   Google Scholar
• Fechtner RD, Mc Carroll KA, Lines CR, et al. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 2005;21: 242–9
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, et al. For the dorzolamide/ timolol study group. The efficacy and safety of the dorzolamidetimolol combination versus the concomitant administration of its components. Ophthalmology 1998;105:1936–44
   Google Scholar
• Konstas AGP, Maltezos A, Bufidis T, et al. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye 2000;14:73–7
   PubMed Web of Science ®Google Scholar
• Coleman AL, Lerner F, Berstein P, et al., for the lumigan/ Cosopt study group. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003;110:2362–8
   Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453–7
   PubMed Web of Science ®Google Scholar
• Liu JH, Zhang X, Kripke DF, et al. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003;44:1586–90
   PubMed Web of Science ®Google Scholar
• Wax MB, Camras CB, Fiscella RG, et al. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol 2002;133:S1–10
   PubMed Web of Science ®Google Scholar